文献速递细菌感染、耐药与抗菌药物医院感染防控

快速检测改善革兰阳性菌血流感染结局与抗菌药物管理

Improving outcomes and antibiotic stewardship (IOAS) for patients with Gram-positive bloodstream infections through use of rapid testing: a quasi-experimental multicentre study of the Accelerate PhenoTest™ BC Kit.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

这项多中心准实验研究分析了AXDX快速鉴定与药敏检测对革兰阳性菌血流感染的影响,比较实施前后患者的临床与抗菌药物管理指标。结果显示,实施后达到最佳治疗时间从36.3小时缩短至20.4小时,首次抗生素调整时间及不必要的MRSA覆盖时间均显著减少。

要点

  • AXDX快速检测缩短革兰阳性菌血流感染达到最佳治疗时间。
  • 快速检测减少不必要的MRSA覆盖时间和抗生素调整延迟。
  • 急性肾损伤发生率有下降趋势但未达统计学显著。

核心结论

  • 实施AXDX快速检测可缩短革兰阳性菌血流感染患者达到最佳治疗的时间,并通过更快的抗生素调整减少不必要的抗生素暴露。

研究设计与样本

  • 多中心准实验研究,纳入219例革兰阳性菌血流感染住院患者,其中pre-AXDX组109例,post-AXDX组110例,比较传统鉴定药敏与AXDX快速检测的效果。

主要发现

  • 中位达到最佳治疗时间pre-AXDX组为36.3小时(IQR 16.9-56.7),post-AXDX组为20.4小时(IQR 7.5-36.7),P=0.01。
  • 中位首次抗生素调整时间pre-AXDX组为29.1小时,post-AXDX组为15.9小时,P=0.002。
  • 中位首次革兰阳性菌抗生素调整时间pre-AXDX组为33.2小时,post-AXDX组为17.2小时,P=0.003。
  • 中位不必要MRSA覆盖时间pre-AXDX组为58.4小时,post-AXDX组为29.7小时,P=0.04。
  • 急性肾损伤发生率post-AXDX组有下降趋势(24% vs 13%,P=0.06),其他次要结局两组无差异。

临床怎么用

  • 对革兰阳性菌血流感染患者,采用AXDX快速鉴定与药敏检测可加速抗生素调整,缩短达到最佳治疗时间并减少不必要的MRSA覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data from the Improving Outcomes and Antibiotic Stewardship for Patients with Bloodstream Infections: Accelerate PhenoTest™ BC Kit (AXDX) Registry Study were analysed to determine the impact of rapid organism identification and antimicrobial susceptibility testing (AST) for Gram-positive bacteraemia. PATIENTS AND METHODS: This multicentre, quasi-experimental study evaluated clinical and antimicrobial stewardship metrics following the implementation of AXDX. Data from hospitalized patients with bacteraemia were compared between groups, one that underwent testing on AXDX (post-AXDX) and one that underwent traditional identification and AST (pre-AXDX). An analysis of patients with Gram-positive bacteraemia was performed. The primary outcome was time to optimal therapy (TTOT). Secondary outcomes included time to first antibiotic modification (overall and Gram-positive), duration of unnecessary MRSA coverage, incidence of adverse events, length of stay and mortality. RESULTS: A total of 219 (109 pre-AXDX, 110 post-AXDX) patients with Gram-positive bacteraemia were included. Median TTOT was 36.3 h (IQR, 16.9-56.7) in the pre-AXDX group and 20.4 h (IQR, 7.5-36.7) in the post-AXDX group (P = 0.01). Compared with pre-AXDX, median time to first antibiotic modification (29.1 versus 15.9 h; P = 0.002), time to first Gram-positive antibiotic modification (33.2 versus 17.2 h; P = 0.003) and median duration of unnecessary MRSA coverage (58.4 versus 29.7 h; P = 0.04) were reduced post-AXDX. A trend towards decreased acute kidney injury (24% versus 13%; P = 0.06) was observed in the post-AXDX group. Groups did not differ in other secondary outcomes. CONCLUSIONS: Implementation of AXDX testing for patients with Gram-positive bacteraemia shortened the TTOT and reduced unnecessary antibiotic exposure due to faster antibiotic modifications.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. MacVane SH, Bhalodi AA, Dare RK, et al. Improving outcomes and antibiotic stewardship (IOAS) for patients with Gram-positive bloodstream infections through use of rapid testing: a quasi-experimental multicentre study of the Accelerate PhenoTest™ BC Kit. J Antimicrob Chemother. 2021. PMID: 34021752. doi:10.1093/jac/dkab165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。